A5102000202- Neurofibromatosis and Schwannoma Cases
- Neuroblastoma Research and Treatments
- Meningioma and schwannoma management
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Ovarian cancer diagnosis and treatment
- Neonatal and fetal brain pathology
- Cancer, Hypoxia, and Metabolism
- Non-Invasive Vital Sign Monitoring
- Preterm Birth and Chorioamnionitis
- Immune cells in cancer
- Ocular Oncology and Treatments
- Ear and Head Tumors
- Colorectal and Anal Carcinomas
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Protein Tyrosine Phosphatases
- Brain Metastases and Treatment
- Cancer-related Molecular Pathways
- Cytokine Signaling Pathways and Interactions
- Head and Neck Cancer Studies
- Cancer Research and Treatments
- Peptidase Inhibition and Analysis
- Gestational Trophoblastic Disease Studies
First Affiliated Hospital of Anhui Medical University
2025
Anhui Medical University
2025
Massachusetts General Hospital
2021-2024
Harvard University
2021-2024
Tianjin Medical University Cancer Institute and Hospital
2019
Normalizing the tumor microenvironment with losartan prevents tumor-induced hearing loss and enhances radiation response in schwannoma rodent models.
Abstract Background Neurofibromatosis 2 (NF2) is an inherited disorder caused by bi-allelic inactivation of the NF2 tumor suppressor gene. NF2-associated tumors, including schwannoma and meningioma, are resistant to chemotherapy, often recurring despite surgery and/or radiation, have generally shown cytostatic response signal transduction pathway inhibitors, highlighting need for improved cytotoxic therapies. Methods Leveraging data from our previous high-throughput drug screening in...
Patients with Schwannomatosis (SWN) overwhelmingly present intractable, debilitating chronic pain. There are no effective therapies to treat SWN. The drivers of pain response and tumor progression in SWN not clear. is proportionally linked size always relieved by resection, suggesting that mechanisms other than mechanical nerve compression exist cause research limited the lack clinically-relevant models. Here, we established novel patient-derived xenograft (PDX) models, dorsal root ganglia...
Abstract Background: Ovarian Cancer (OvCa) is the most lethal gynecologic malignancy worldwide. The use of immune checkpoint inhibitors (ICIs) has revolutionized therapy several malignancies. Unfortunately, ICIs have had limited efficacy in OvCa, with objective response rates only 10 to 15% patients. Prevailing preclinical and clinical data indicate that abnormalities tumor microenvironment (TME) contribute immunosuppression dictate outcome ICIs. OvCa harbors an abnormal TME, characterized...
NF2-related Schwannomatosis (NF2-SWN) is a disease that needs new solutions. The hallmark of NF2-SWN, dominantly inherited neoplasia syndrome, bilateral vestibular schwannomas (VSs), which progressively enlarge, leading to sensorineural hearing loss, tinnitus, facial weakness, and pain translates social impairment clinical depression. Standard treatments for growing VSs include surgery radiation therapy (RT); however, both carry the risk further nerve damage can result in deafness palsy....
Abstract NF2 -related schwannomatosis ( -SWN) is a progressive and disabling disease requiring effective treatments. The hallmark of -SWN bilateral vestibular schwannomas (VSs), which progressively enlarge, leading to permanent sensorineural hearing loss severely impacting patients’ quality life. Currently, there are no FDA-approved drugs for VS or the associated loss. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but not yet been systematically investigated in...
Abstract Ovarian cancer (OvCa) is the most lethal of gynecologic malignancies. Immune checkpoint inhibitors, which have revolutionized treatment multiple malignancies, had limited efficacy in OvCa patients. Here, using syngeneic models and genetic pharmacologic perturbations, we discovered that losartan – a widely prescribed anti-hypertensive drug exhibits dual effects on both tumor microenvironment cells to sensitize chemo-immunotherapy. Specifically, i) reprograms leading increased...
<h3>Background</h3> Schwannomatosis (SWN) is a genetic disorder characterized by multiple non-malignant schwannomas growing on the spine and peripheral nerves. Patients with SWN overwhelmingly present intractable, debilitating chronic pain, severe enough to cause permanent disability. The etiology of pain in not clear, development novel treatments for related has been extremely slow inefficient. Treatment limited invasive surgery, which carries significant risks further nerve damage. No drug...